Cancer Network spoke with Marleen Meyers, MD, about evidence on low-dose tamoxifen vs placebo in women who had surgery for their ductal carcinoma in situ.
Cancer Network spoke with Marleen Meyers, MD, a medical oncologist at NYU Langone Perlmutter Cancer Center in New York City, who specializes in the treatment and care of patients with breast cancer, about the results of a phase III trial, TAM-01. This trial examined the potential benefit of low-dose tamoxifen compared with placebo in women who had surgery for their ductal carcinoma in situ (DCIS). The results of the trial were presented this past December at the annual 2018 San Antonio Breast Cancer Symposium (SABCS).
Stay up to date on recent advances in the multidisciplinary approach to cancer.
The Proper Ways to Identify and Use ADCs in Breast Cancer Subtypes
June 29th 2025Deciding when to use immunotherapy and how to utilize antibody-drug conjugates are complicated processes that require multidisciplinary collaboration to ensure that all patients with breast cancer receive appropriate and efficient care.
Cardio-Oncology Considerations for Breast Cancer: Risk Stratification, Monitoring, and Treatment
June 26th 2025Survivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.